Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) has provided an announcement.
Roquefort Therapeutics has announced the determination of the record date for entitlement to new unlisted redeemable non-voting shares, linked to its Midkine Investments portfolio. Shareholders and convertible loan note holders as of November 30, 2025, will be eligible for these shares, which aim to facilitate future distribution of Midkine Investments shares, enhancing shareholder value.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on acquiring exclusive license rights to novel drug alternatives for cancer treatment. The company is currently engaged in a transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. to obtain rights to AO-252, targeting the TACC3 protein.
Average Trading Volume: 2,733,210
Technical Sentiment Signal: Sell
Current Market Cap: £3.23M
Learn more about ROQ stock on TipRanks’ Stock Analysis page.